Complete response of secukinumab in palmoplantar psoriasis
نویسندگان
چکیده
منابع مشابه
[Good response of hyperkeratotic palmoplantar psoriasis to ustekinumab].
Although only a small area of the body is affected in palmoplantar psoriasis or psoriasis of the palms and soles, this condition causes considerable functional impairment due to hyperkeratosis, fissures, and erythema, and occasionally inflammation and pustules. These symptoms may seriously interfere with the patient’s quality of life and may be disabling. Moreover, the lack of a standard treatm...
متن کاملSuccessful use of secukinumab in pustular psoriasis
BSA: body surface area DLQI: Dermatology Life Quality Index IL-17A: interleukin-17A PASI: Psoriasis Area and Severity Index INTRODUCTION Psoriasis is a common chronic immunologic condition of the skin and nails that affects approximately 2% of the population and is characterized by red elevated plaques with silvery scale. Various forms exist, of which, chronic plaque psoriasis is most common, o...
متن کاملProfile of secukinumab in the treatment of psoriasis: current perspectives
Secukinumab (Cosentyx™) is a human monoclonal IgG1k antibody that has been developed to target and block the actions of IL-17A. It is known that this cytokine is elevated in lesions of psoriasis. Interleukins in the Th17 pathway play a pivotal role in the pathogenesis of psoriasis and have thus become targets for recent biologic drug development. As a monoclonal antibody immune modulator, secuk...
متن کاملSecondary Syphilis Presenting As Palmoplantar Psoriasis
In a recent past, the incidence of syphilis has increased in various geographical regions. The authors describe a case of secondary syphilis mimicking palmoplantar psoriasis.
متن کاملSecukinumab in plaque psoriasis--results of two phase 3 trials.
BACKGROUND Interleukin-17A is considered to be central to the pathogenesis of psoriasis. We evaluated secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe plaque psoriasis. METHODS In two phase 3, double-blind, 52-week trials, ERASURE (Efficacy of Response and Safety of Two Fixed Secukinumab Regimens in Psoriasis) and FIXTURE (Full Year Inve...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Dermatology Online Journal
سال: 2017
ISSN: 1087-2108
DOI: 10.5070/d32310037014